AUTH/2325/6/10: Doctor v Boehringer Ingelheim – HSJ stroke “Special Report” (no breach) | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2325/6/10
Complainant	Doctor
Company	Boehringer Ingelheim
Material	Four-page HSJ “Special Report” / described on HSJ cover as a “Preventing stroke and cutting costs supplement”
Publication / date	Health Service Journal, 3 June 2010
Issue alleged	Disguised promotion / resembled independent editorial matter
Applicable Code year	2008
Clause(s) cited	Clause 12.1
Panel decision	No breach (material not considered promotional)
Appeal	Yes (by complainant); unsuccessful
Appeal Board rationale	Raised disease awareness and company profile but did not promote specific medicines; therefore not promotional under Clause 1.2 and could not be disguised promotion
Complaint received	9 June 2010
Case completed	8 September 2010

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A doctor complained about a four-page Health Service Journal (HSJ) piece titled ‘Preventing Stroke Special Report; “Action or crisis”’ (3 June 2010), stated to be “paid for and sponsored by Boehringer Ingelheim”.
The complainant alleged the piece resembled independent editorial matter (same colour scheme, typeface, graphics, spacing, columns, text boxes, call-outs, captions etc as the journal), and therefore breached the Code’s requirements on disguised promotion.
Boehringer Ingelheim said it funded the piece as an unrestricted educational grant; HSJ commissioned and produced it, and Boehringer’s only involvement was factual accuracy checking (no editorial control).
The Panel first assessed whether the material was promotional; it concluded it did not promote the prescription, supply, sale or administration of Boehringer Ingelheim medicines.
The complainant appealed, citing earlier HSJ supplement cases (AUTH/2287/12/09 and AUTH/2288/12/09) where Clause 12.1 breaches were found.
The Appeal Board upheld the Panel: the material raised disease awareness and Boehringer’s profile but did not promote specific medicines; therefore it was not promotional and could not be disguised promotion.

⚖️

⌄

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access